ReviewCell biochemistry and biophysics2026
Cardioprotective Role of Calhex
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are a major burden on the global population. This causes structural deterioration and disruption of the myocardium. A multitude of studies has demonstrated that an elevation in intracellular calcium (Ca2+)i through the calcium-sensing receptor (CaSR) is associated with the onset of various CVDs. CaSR is believed to be involved in different processes, including proliferation, differentiation, cell death, gene regulation, and hormonal secretion. Calhex231 is a calcilytic drug, which negatively modulates CaSR and attenuates (Ca2+)i influx. Calhex231 has shown a therapeutic implication in the realm of cardiac fibrosis, remodeling, hypertrophy, myocardial infarction (MI), cardiomyopathies, pulmonary artery hypertension, myocardial ischemia-reperfusion injury (IR), and heart failure (HF). Numerous studies demonstrated Calhex231 has shown cardioprotection through various signaling pathways and reduced damage to organelles within cells. This review aims to establish its potential utility in managing a number of CVDs and associated post-complications.
Indexed as
Identifiers
41335293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.